Cargando…
S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428425/ http://dx.doi.org/10.1097/01.HS9.0000967944.12345.32 |
| _version_ | 1785090466099757056 |
|---|---|
| author | Demaria, Olivier Habif, Guillaume Le Floch, Francois Muller, Marianna Chiossone, Laura Remark, Romain Vetizou, Marie Maurel, Nadia Morel, Ariane Gauthier, Laurent Morel, Yannis Paturel, Carine Vivier, Eric |
| author_facet | Demaria, Olivier Habif, Guillaume Le Floch, Francois Muller, Marianna Chiossone, Laura Remark, Romain Vetizou, Marie Maurel, Nadia Morel, Ariane Gauthier, Laurent Morel, Yannis Paturel, Carine Vivier, Eric |
| author_sort | Demaria, Olivier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428425 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284252023-08-17 S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS Demaria, Olivier Habif, Guillaume Le Floch, Francois Muller, Marianna Chiossone, Laura Remark, Romain Vetizou, Marie Maurel, Nadia Morel, Ariane Gauthier, Laurent Morel, Yannis Paturel, Carine Vivier, Eric Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428425/ http://dx.doi.org/10.1097/01.HS9.0000967944.12345.32 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Demaria, Olivier Habif, Guillaume Le Floch, Francois Muller, Marianna Chiossone, Laura Remark, Romain Vetizou, Marie Maurel, Nadia Morel, Ariane Gauthier, Laurent Morel, Yannis Paturel, Carine Vivier, Eric S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_full | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_fullStr | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_full_unstemmed | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_short | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_sort | s258: iph6501 is a first-in-class tetraspecific antibody-based natural killer cell engager therapeutic developed for the treatment of b-cell non-hodgkin’s lymphomas |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428425/ http://dx.doi.org/10.1097/01.HS9.0000967944.12345.32 |
| work_keys_str_mv | AT demariaolivier s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT habifguillaume s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT leflochfrancois s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT mullermarianna s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT chiossonelaura s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT remarkromain s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT vetizoumarie s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT maurelnadia s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT morelariane s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT gauthierlaurent s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT morelyannis s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT paturelcarine s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT viviereric s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas |